Wegener’s Lung Disease (Granulomatosis with Polyangiitis) – A Patient‑Friendly Guide

Overview

Wegener’s lung disease is the historical name for Granulomatosis with polyangiitis (GPA), a rare autoimmune vasculitis that primarily affects small‑ to medium‑sized blood vessels in the respiratory tract and kidneys. When the disease involves the lungs, patients experience inflammation of the airways, lung tissue, and surrounding structures, leading to symptoms such as persistent cough, shortness of breath, and hemoptysis (coughing up blood).

GPA can occur at any age but most commonly presents in adults aged 40–60 years. It is slightly more common in men than women, and the incidence varies by region, ranging from 0.9 to 2.0 cases per million people per year worldwide ^[1][2]. Although rare, early recognition is crucial because untreated GPA can progress rapidly and be life‑threatening.

Symptoms

Because GPA can affect multiple organ systems, symptoms are often diverse. The most frequent lung‑related manifestations are listed first, followed by systemic signs.

Respiratory Symptoms

• Chronic cough – often dry, but may become productive as disease progresses.
• Shortness of breath (dyspnea) – may be exertional or occur at rest in severe cases.
• Hemoptysis – coughing up blood; a red‑flag symptom that warrants urgent evaluation.
• Chest pain – pleuritic (sharp, worsens with breathing) or due to granulomatous nodules.
• Wheezing or noisy breathing – can mimic asthma.
• Recurrent sinus infections – often precede lung disease and may cause chronic nasal congestion.

Systemic Symptoms

• Fever – low‑grade or intermittent.
• Fatigue & malaise – common in inflammatory conditions.
• Weight loss – unintended, due to chronic inflammation.
• Joint pain (arthralgia) or arthritis – usually non‑erosive.
• Kidney involvement – hematuria, proteinuria, swelling of ankles; may progress to renal failure.
• Skin lesions – palpable purpura, ulcers, or livedo reticularis.
• Eye irritation – redness, pain, or vision changes from orbital involvement.

Causes and Risk Factors

The exact trigger for GPA remains unknown, but research points to a combination of genetic predisposition and environmental exposures that provoke an abnormal immune response.

Potential Causes

• Autoimmune dysregulation – the body produces antineutrophil cytoplasmic antibodies (ANCA), most often proteinase‑3 (PR3‑ANCA), that attack blood vessel walls.
• Genetic factors – certain HLA‑DQ and HLA‑DR alleles increase susceptibility ^[3].
• Environmental triggers – exposure to silica dust, certain drugs (e.g., propylthiouracil, hydralazine), and infections have been linked to onset in case‑control studies.

Risk Factors

• Age 40–60 years (peak incidence).
• Male sex (slightly higher prevalence).
• History of smoking – although not a direct cause, smoking worsens lung involvement.
• Occupational exposure to silica or metal dust.
• Family history of autoimmune disease (e.g., rheumatoid arthritis, lupus).

Diagnosis

Diagnosing GPA requires a combination of clinical assessment, laboratory testing, imaging, and sometimes tissue biopsy. Early referral to a rheumatologist or pulmonologist experienced with vasculitis is essential.

Clinical Evaluation

• Detailed medical history focusing on ENT, respiratory, renal, and systemic symptoms.
• Physical examination: auscultation for crackles or wheezes, skin inspection, sinus exam, and blood pressure check.

Laboratory Tests

• ANCA testing – PR3‑ANCA (c‑ANCA) is positive in ~70‑80 % of patients with active GPA; MPO‑ANCA (p‑ANCA) is less common.
• Complete blood count (CBC) – may show anemia or leukocytosis.
• Renal function panel – serum creatinine, urinalysis for hematuria/proteinuria.
• Inflammatory markers – ESR and CRP are usually elevated.

Imaging

• Chest X‑ray – reveals nodules, cavitary lesions, or infiltrates.
• High‑resolution CT (HRCT) of the chest – better characterizes nodules, ground‑glass opacities, and airway thickening; essential for monitoring disease progression.
• CT of sinuses – evaluates ENT involvement.

Biopsy

Histopathologic confirmation is the gold standard. Options include:

• Transbronchial or surgical lung biopsy – shows necrotizing granulomatous inflammation and vasculitis.
• Kidney biopsy – often performed if renal involvement is suspected.
• Sinus or skin biopsy – less invasive alternatives.

Diagnostic Criteria

The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) classification criteria assign points for ANCA status, imaging, biopsy findings, and clinical features. A total score ≥ 5 classifies the patient as having GPA ^[4].

Treatment Options

Therapy aims to induce remission quickly, then maintain disease control while minimizing drug toxicity.

Induction Therapy (First 3–6 months)

• Glucocorticoids – oral prednisone 1 mg/kg/day (max ≈ 60 mg) with a rapid taper over 4–6 weeks. Intravenous methylprednisolone pulses (500–1000 mg/day for 3 days) are used for severe pulmonary hemorrhage.
• Rituximab – anti‑CD20 monoclonal antibody; 375 mg/m² weekly for 4 weeks or two 1 g infusions 2 weeks apart. Preferred over cyclophosphamide for many patients due to a better safety profile ^[5].
• Cyclophosphamide – oral (2 mg/kg/day) or IV pulsed (15 mg/kg every 2–3 weeks) for patients intolerant of rituximab or with life‑threatening disease.

Maintenance Therapy (After remission)

• Azathioprine 2–2.5 mg/kg/day.
• Mycophenolate mofetil 1–1.5 g twice daily.
• Rituximab – 500 mg every 6 months for 2–5 years, based on ANCA titers and clinical status.
• Low‑dose glucocorticoids (<10 mg/day) are often continued for the first 12 months of maintenance.

Adjunctive Treatments

• Plasma exchange (PLEX) – considered for severe pulmonary hemorrhage or rapidly progressive glomerulonephritis.
• Prophylaxis for opportunistic infections: trimethoprim‑sulfamethoxazole for Pneumocystis jirovecii, antiviral prophylaxis if on high‑dose steroids.
• Vaccinations – influenza, pneumococcal, COVID‑19 (non‑live vaccines) before immunosuppression.

Lifestyle Modifications

• Smoking cessation – essential to protect lung tissue.
• Balanced diet rich in protein, calcium, and vitamin D to counter steroid‑induced bone loss.
• Regular, moderate exercise as tolerated to maintain cardiovascular fitness.
• Stress‑management techniques (mindfulness, yoga) to help cope with chronic illness.

Living with Wegener’s Lung Disease

Managing GPA is a lifelong endeavor that blends medical treatment with day‑to‑day self‑care.

Practical Tips

• Medication adherence – use pill organizers or smartphone reminders; never stop steroids abruptly.
• Regular monitoring – schedule labs (CBC, renal panel, ANCA) every 1–3 months during induction, then every 3–6 months in remission.
• Follow‑up imaging – chest CT every 6–12 months or sooner if symptoms change.
• Protect your lungs – avoid occupational dust, use air purifiers at home, wear masks in polluted environments.
• Bone health – baseline DEXA scan; consider calcium 1000–1200 mg/day, vitamin D 800–1000 IU/day, and bisphosphonate therapy if on long‑term steroids.
• Vaccination calendar – keep an updated record; avoid live vaccines while immunosuppressed.
• Support networks – connect with vasculitis patient groups, counselors, or social workers.

Psychosocial Considerations

Chronic disease can lead to anxiety, depression, or feelings of isolation. Cognitive‑behavioral therapy, peer‑support groups, and, when needed, pharmacologic treatment for mood disorders improve quality of life ^[6].

Prevention

Because the exact cause is not fully understood, primary prevention is limited. However, risk can be reduced by:

• Quitting smoking and avoiding secondhand smoke.
• Wearing protective equipment (respirators) when working with silica, dust, or chemicals.
• Prompt treatment of chronic sinus or respiratory infections to reduce chronic inflammation.
• Monitoring for drug‑induced vasculitis; inform physicians of any new medications, especially propylthiouracil or hydralazine.

Complications

If left untreated or poorly controlled, GPA can cause serious, potentially irreversible damage.

• Diffuse alveolar hemorrhage – life‑threatening bleeding into the lungs.
• Permanent lung fibrosis – reduces lung capacity and may require supplemental oxygen.
• Renal failure – up to 30 % progress to end‑stage kidney disease requiring dialysis.
• Upper airway obstruction – subglottic stenosis can cause stridor and require surgical intervention.
• Serious infections – immunosuppressive therapy predisposes to bacterial, viral, and fungal infections.
• Osteoporosis and avascular necrosis – due to prolonged corticosteroid use.
• Increased risk of malignancy – especially bladder cancer with cyclophosphamide, and skin cancers with chronic immunosuppression.

When to Seek Emergency Care

---

References:
[1] Fauci AS, et al. Harrison's Principles of Internal Medicine. 20th ed. 2018.
[2] Jennette JC, et al. "2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides." Arthritis Rheum. 2013;65(1):1‑11.
[3] Lyons PA, et al. "Genetic susceptibility loci in ANCA-associated vasculitis." Nat Genet. 2020;52:972‑978.
[4] Mukhtyar C, et al. "2022 ACR/EULAR Classification Criteria for Granulomatosis with Polyangiitis." Ann Rheum Dis. 2022;81:662‑669.
[5] Jones RB, et al. "Rituximab versus cyclophosphamide for ANCA-associated vasculitis." N Engl J Med. 2010;363:221‑232.
[6] Sagné C, et al. "Psychological impact of chronic vasculitis and strategies for care." Rheumatology. 2021;60: 2117‑2124.
All information is for educational purposes and should not replace professional medical advice.